Japan· JP-4490409G1022
トラロキヌマブ（遺伝子組換え）
A tralokinumab product containing トラロキヌマブ（遺伝子組換え）, registered in Japan by レオファーマ, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Tralokinumab is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AH07 (tralokinumab), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Tralokinumab · ATC D11AH07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tralokinumab costs, country by country.
Normalised to the WHO defined daily dose (16.1 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tralokinumab · price per daily dose (16.1 mg)
USD · FX 28 Sept 2026
- CH Switzerland$34.49
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- トラロキヌマブ（遺伝子組換え）
- Manufacturer
- レオファーマ
- Country
- Japan (JP)
- ATC code
- D11AH07
- ATC class
- Tralokinumab
- Defined daily dose
- 16.1 mg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tralokinumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaADTRALZALEO Pharma A/S, Ballerup
- CanadaADTRALZALEO PHARMA INC
- SwitzerlandAdtralza
- SpainADTRALZA 150 mg SOLUCION INYECTABLE EN JERINGA PRECARGADALeo Pharma A/S
- FinlandAdtralzaLeo Pharma A/S
- FranceADTRALZA 150 mg, solution injectable en seringue préremplieLEO PHARMA A/S (DANEMARK)
- United KingdomAdtralza 150mg/1ml solution for injection pre-filled syringesLEO Pharma
- IrelandAdtralza 150 mg solution for injection in pre-filled syringeLEO Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Adtralza
- Iceland · Adtralza
- Liechtenstein · Adtralza
- Norway · Adtralza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8a8c9f7f-eaab-4a2d-ace0-e9ddfe508030 GET /v1/drugs/8a8c9f7f-eaab-4a2d-ace0-e9ddfe508030?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１５０ｍｇ１ｍＬ１筒",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4490409G1022",
"category": "注射薬",
"price_yen": 24182,
"generic_name": "トラロキヌマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "4490",
"transitional_expiry": null
}See everything about tralokinumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.